The world is currently racing for a vaccine to the COVID-19 virus. There are over 25 companies with vaccines in clinical trials. So who is going to get there first, and does first to the finish line mean first place in the vaccine race? In this video, WX Capital takes a look at this race and analyzes the companies in this collaborative battle. We found the 5 most likely companies to succeed in this race and take a deep look at their positions in this race and the development of their COVID vaccines. From a company with a COVID vaccine already in use by humans to companies with COVID vaccines in phase 3 of development, everything is considered.

The Top 5 Leading Companies in the Race for the COVID Vaccine:
Honorable Mention - GSK & SANOFI
5) CanSino Biologics
4) Johnson & Johnson
3) Moderna
2) Pfizer
1) AstraZeneca

EDIT: 2:12 - A Russian COVID Vaccine was approved

► Website (Check us out!): https://www.wx.capital/
► See our RESEARCH: https://www.wx.capital/public-research
► Facebook:   / wxcapitalus  
► Instagram:   / wx.capital  
► Twitter:   / wxcapital  
► Linkedin:   / wxca.  .

1: AstraZeneca/Oxford (CHAD-OX1):
- Using CHAD-OX1 based on Oxford technology. Weakened version of an adenovirus that infects chimps, so most people shouldn't be resistant.
- First to start phase 3 trials, announcing on June 27th that a 5 K participant trial in Brazil had begun, Results may be ready in August/September.
- Lent vaccine production capabilities from Catalent. They are the farthest along in terms of lining up the manufacturing capabilities, as they have orchestrated a network of more than 20 contract manufacturers to rapidly create 2 billion doses.

2: Pfizer (BNT162b2):
- Co-dev. With German mRNA company BioNTech, in Phase I/II
- Just announced they are starting phase 2/3 trials with 30 K participants and 120 sites globally.
- Had four shots on goal in phase 1/2, with different versions of the bits of COVID that are needed to generate an immune response.
- They are aiming to gain regulatory approval by this October, with 100 M doses by the end of 2020 and 1.3 B by end of 2021.
- Already has a deal with the U.S. govt for 50 M innoculations at a price of $2 B. It has also signed deals with UK and Japan

3: Moderna (MRNA-1273):
- Moderna's specialty in mRNA allowed them to get on COVID vaccine quick, and they came out as the early leader in the vaccine race by starting trials in mid march.
- They blew through the development, starting a phase 2 in mid may and now Starting large-scale phase 3 trial in July of 30 K people. Stock has tripled since they got into the race. Even got a shoutout from Mike Pence about starting their phase 3.
- However, executives in the company have been selling off their shares at an alarming rate, which has cast some doubt over their own confidence in their vaccine.

4: J&J (Ad26.COV2.S):
- Uses an adenovirus vector to deliver a gene for coronavirus antigen into cells
- Phase 1 going on in Belgium and the U.S.
- Published results in the prestigious Nature showing a single dose provided complete or near-complete protection in monkeys. This one is special because it only requires one dose.
- Blazing through the trials, they are aiming to start a Phase III in September.
- Signed a deal with the U.S. govt to 100 M doses for $1 B

5: CanSino:
- Major China player.
- Adenovirus-based vector was used for Ebola vaccines.
- Jointly developed by Institute of Biotech as part of Academy of Military Medical Sciences.
- About to start Phase III trials, and is already approved by the Chinese government to be used for military personnel.
- The virus delivers a protein used by COVID to immune cells called antigen presenting cells, which activates a T cell response.
- One issue is using AAV5, which many people are already immune to. Currently, has manufacturing capacity to produce 100 M/yr.

-------------------------------------------------------------------------------------------------------------------------
Who we are:

WX Capital is led by ex-life science consultants and ex-bankers who have attained over 35% annually by investing in biotech stocks.

We've decided to share our biotech expertise through our affordable subscription service, where members receive real-time stock trades, market updates, and exclusive access to stock diligence. Join today and get a leg up in the market! Sign-up today for our free weekly newsletter on market trends and stock performance. Or try out a free trial to experience everything we offer!

► Join Here: https://www.wx.capital/subscribe

DISCLAIMER:

This content is strictly for educational purposes, and should not be taken as financial and or investment advice. The publisher of this video assumes no responsibility for your trading performance as a result of watching one of these videos.

#Moderna #AstraZeneca #COVIDVaccine